With 800+ staff members across 21 countries, Synteract is an innovative, full-service contract research organization supporting biopharma companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted 4,000+ studies in 60+ countries, contributing to more than 240 product approvals. We offer notable expertise in oncology, pediatrics, dermatology, neuro degenerative, rare/orphan, and other indications.
Oncology - In the past 5 years, Synteract has managed 175+ oncology trials, many in complex treatments like pathway-targeted therapies, chemotherapy, immunotherapy, cell-based and gene therapies. We were the first CRO to begin work in immunotherapy more than 10 years ago.
Pediatrics - We have conducted 95+ pediatric clinical trials globally, in 17 indications. Our pediatric cross-functional team helps clients navigate complex research to allow medicines to serve the littlest ones.
Dermatology – Our acquisition of dermatology specialist CRO Cu-Tech, combined with Synteract’s many years in dermatology, uniquely positions us as the leading dermatology CRO. We have conducted more than 230 derm trials, in 20+ indications of dermatologic diseases and skin care products.
Neuro Degenerative – We’ve managed 140+ neuro degenerative trials in the last 5 years, with extensive experience in drugs addressing Alzheimer’s, Parkinson’s, ALS, MS, migraine, schizophrenia, and more.
Rare & Orphan - We have conducted 100+ trials in rare or orphan diseases in the past 5 years alone. We specialize in unique studies that affect a small portion of the population or are otherwise “forgotten” by other treatments.
Discover how we can support your clinical trials. Visit www.synteract.com or contact us today!